Edited by
DAVID J. GOLDSTEIN

2005

The first edition of The Management of Eating Disorders and Obesity was published in 1999, just after the removal of fenfluramine and dexfenfluramine from the market because of the association of their use with development of valvular heart disease. Dr. Albert J. Stunkard expressed the possibility that drug therapy would come to a “screeching halt” and that legal actions would cause prescribers to avoid obesity pharmacotherapies and cause pharmaceutical companies to discontinue development of future obesity therapies.